Gilead and Tibotec continue agreement with another HIV combo
This article was originally published in Scrip
Executive Summary
Gilead Sciences has entered into a license agreement with Johnson & Johnson's Tibotec Pharmaceuticals for the development and commercialisation of a single-tablet regimen combining Tibotec’s Prezista (darunavir) with three Gilead products: Emtriva (emtricitabine); its investigational agent GS 7340 (a prodrug of tenofovir) and cobicistat, a boosting agent.